Cooper Institute for Advanced Reproductive MedicineDecember 9, 2022

FDA 483 - Cooper Institute for Advanced Reproductive Medicine - December 09, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cooper Institute for Advanced Reproductive Medicine

Record Details

The Cooper Institute for Advanced Reproductive Medicine was cited for multiple deficiencies related to human reproductive tissue establishment operations. The inspection revealed failures in testing oocyte donors for communicable diseases like West Nile Virus, incomplete donor screening questionnaires, and inadequate record retention for HCT/Ps. Additionally, the firm lacked standard operating procedures for handling CMV-positive donors and for overall donor testing, screening, and eligibility determination.

Company: Cooper Institute for Advanced Reproductive Medicine
Inspection Date: December 9, 2022
Product Type: Biologics
Office: Division of Human and Animal Food Operations - West III
Person: Gloria A. Milster

Open in Dashboard

ID · 9593851c-8051-4c29-9f1b-122aa7ab233e